Ra Medical Systems, Inc. is a commercial-stage medical device company. It develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company's product pipeline consists of DABRA which is a minimally-invasive excimer laser and disposable catheter system used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of peripheral artery disease, or above- and below-the-knee. Pharos Excimer Laser is a powerful 308 nm ultraviolet-B excimer laser used by physicians as a tool to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma. Ra Medical Systems, Inc. is based in Carlsbad, California.
Revenue (Most Recent Fiscal Year) | $7.20M |
Net Income (Most Recent Fiscal Year) | $-56.96M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 4.44 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.66 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -771.89% |
Net Margin (Trailing 12 Months) | -772.04% |
Return on Equity (Trailing 12 Months) | -120.68% |
Return on Assets (Trailing 12 Months) | -85.93% |
Current Ratio (Most Recent Fiscal Quarter) | 4.62 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.30 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
Inventory Turnover (Trailing 12 Months) | 2.18 |
Book Value per Share (Most Recent Fiscal Quarter) | $61.81 |
Earnings per Share (Most Recent Fiscal Quarter) | $-3.25 |
Earnings per Share (Most Recent Fiscal Year) | $-108.25 |
Diluted Earnings per Share (Trailing 12 Months) | $-46.00 |
Exchange | NYSE |
Sector | Healthcare |
Industry | Medical Devices |
Common Shares Outstanding | 2.92M |
Free Float | 2.85M |
Market Capitalization | $20.35M |
Average Volume (Last 20 Days) | 0.26M |
Beta (Past 60 Months) | 1.62 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 2.40% |
Percentage Held By Institutions (Latest 13F Reports) | -- |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |